🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

CONGRESS | #EHA2025 | POSTER Fredrik Schjesvold, Fredrik Schjesvold, OsloMyelomaCenter presents updated results from the phase 1/2 CA057-003 trial of mezigdomide (MEZId) in RRMM (N=56). No new safety signals were identified across all cohorts. ORR - MEZId+TAM: 50%; MEZId+BMS-986158: 35%;

CONGRESS | #EHA2025 | POSTER Yi Lin, Yi Lin, Mayo Clinic Comprehensive Cancer Center, presents results on the association of biomarkers pre-and post-cilta-cel with MNTs and CNP. Significant correlations between absolute lymphocyte count and CAR+ T-cell counts at and around peak expansion. ALC is an

CONGRESS | #EHA2025 | PRESENTATION Aurore Perrot Aurore Perrot, Centre Hospitalier Universitaire de Toulouse, presents results from the TRIMM-3 study, which evaluates the safety and efficacy of talquetamab plus cetrelimab in R/R #multiplemyeloma (N=44). In patients with prior

CONGRESS | #EHA2025 | POSTER Maria-Victoria Mateos, marivi mateos, Universidad de Salamanca, presents updated analysis of MonumentTAL-1 vs LocoMMotion/MoMMent, comparing talquetamab (n=75) vs real-world physicians choice (n=36) in triple-class exposed pts with RRMM. Talquetamab continued to

CONGRESS | #EHA2025 | POSTER Vania Hungria, VaniaHungria, Clínica São Germano, presents HRQoL findings of DVRd (n=197) vs VRd (n=198) in the phase 3 CEPHEUS Trial. Median FU was 58.7 months. Improved HRQoL, physical functioning, and symptom reduction from baseline with DVRd,

CONGRESS | #EHA2025 | POSTER Lærke Sloth Andersen, Rigshospitalet, presents results on risk of infection in pts with smoldering MM (n=188) vs controls (n=810) and pts with MGUS (n=188) from the iStopMM study. Findings show that pts with smoldering MM are at significantly higher

CONGRESS | #EHA2025 | POSTER Shaji Kumar, Shaji Kumar, @mayoclinic, presents results from a real-world Mayo Clinic study investigating outpatient (OP) step-up dosing (SUD) and safety with talquetamab (N=32). Pts who received talquetamab SUD in OP setting had a reduced length of

CONGRESS | #EHA2025 | PRESENTATION Gurbakhash Kaur Gurbakhash Kaur, Mount Sinai Health System, shares the findings from the iMMagine-1 trial, which evaluates the safety and efficacy of anito-cel in R/R #multiplemyeloma (N=117). Anito-cel demonstrated deep and durable responses with ORR (per IMWG

CONGRESS | #EHA2025 | PRESENTATION Enrique Ocio Enrique M Ocio, Hospital Universitario Marqués de Valdecilla, discusses the dose-escalation phase of the LINKER-MM2 trial, which evaluated the safety and efficacy of linvoseltamab plus carfilzomib in R/R #multiplemyeloma (N=23). Durable responses with ORR at

CONGRESS | #EHA2025 | PRESENTATION Xavier Leleu, Clinical Investigation Center of Poitiers, shares preliminary results from the IRAKLIA trial evaluating isatuximab (Isa) SC on-body delivery injector (OBI) vs IV plus pomalidomide and dexamethasone (Pd) in RRMM (N=531). The

CONGRESS | #EHA2025 | PRESENTATION Krzysztof Jamroziak, Medical University of Warsaw, presents results from the PREDATOR-MRD study evaluating daratumumab vs observation in MRD-relapsed MM (N=24). Median EFS (daratumumab vs observation)=NR vs 9.5 months. Re-achievement of MRD

CONGRESS | #EHA2025 | PRESENTATION Shaji Kumar Shaji Kumar Mayo Clinic presents results from the phase II RedirecTT-1 trial of talquetamab + teclistamab in patients with RRMM with EMD. Tal + Tec led to an ORR of 78.9% and a ≥CR rate of 54.4%; efficacy exceeded standard therapies,

CONGRESS | #EHA25 | PRESENTATION Lisa Leypoldt UKE Hamburg shares findings from the PhII GMMG-CONCEPT trial of Isa-KRd in high-risk patients with NDMM (n = 98). Post-consolidation MRD negativity rate at 10-5 was 74.8% in transplant-eligible patients (n = 219), sustained to 1 year

CONGRESS | #EHA25 | PRESENTATION Francesca Gay Università di Torino compares Isa-KRd vs KRd in transplant-eligible patients with NDMM (n = 302) in the PhIII IsKia trial. ▪️ 1-year sustained MRD negativity rate (10-6) was increased with Isa-KRd vs KRd; the additional benefit of adding Isa

CONGRESS | #EHA25 | PRESENTATION Using findings from the ADVANCE trial (n= 306), C. Ola Landgren, M.D. Sylvester Comprehensive Cancer Center proposes Dara-KRd as the new standard for patients with NDMM receiving initial KRd backbone therapy. ▪️ MRD negativity at 10-5 by NGS (primary endpoint) was higher in

CONGRESS | #EHA25 | PRESENTATION Meletios A. Dimopoulos Thanos Dimopoulos University of Athens shares results from Part 1 of the ongoing MagnetisMM-6 trial investigating elranatamab (Q4W from C1D1)+daratumumab+lenalidomide in transplant-ineligible patients with NDMM (n = 37). ▪️ At median

The Multiple Myeloma Hub was pleased to speak with Hang Quach. We asked, How are BCMA-directed BsAbs currently utilized in real-world practice for #MultipleMyeloma? loom.ly/jhvjkaw #mmsm #myeloma #MedEd Hang Quach University of Melbourne

CONGRESS | #EHA2025 | POSTER Meletios Dimopoulos Thanos Dimopoulos presented updated results from the phase III DREAMM-8 study of belantamab mafodotin + pomalidomide + dexamethasone (BPd; n = 155) vs POM + bortezamib + DEX (PVd; n = 147) in patients with RR #myeloma who received ≥1

CONGRESS | #EHA2025 | POSTER Evangelos Terpos University of Athens shared findings from an extended dosing schedule of belantamab mafodotin + DARA + DEX + LEN in patients with ND #myeloma in the phase I/II BelaDRd trial (part 1 n = 24, part 2 n = 12). BelaDRd demonstrated significant